This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Centre Leon Berard, Centre National De La Recherche Scientifique, Korea Institute of Science and Technology. Active years: 2023-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 39 
2 out of 5,383 
2 out of 2,248 
Years Active: 2023-2024
Title: Innovator Spotlight: Ana Hennino and Her Contributions to Pancreatic Cancer Diagnosis
Introduction
Ana Hennino, an accomplished inventor based in Lyons, France, has made significant strides in the field of biomedical diagnostics and treatment. With a total of two patents to her name, her work focuses on non-invasive methods for assessing and treating pancreatic ductal adenocarcinoma (PDAC), a challenging form of cancer.
Latest Patents
Hennino's most recent inventions involve a groundbreaking, non-invasive method for evaluating a subject's risk of having pancreatic ductal adenocarcinoma. This method incorporates the measurement of the βig-h3 protein level in a blood sample. Research conducted on two distinct cohorts of PDAC patients, as well as a PDAC mouse model, has demonstrated that the presence of βig-h3 serves as a reliable biomarker for early tumorigenesis in pancreatic neoplastic lesions. Additionally, Hennino's research has identified βig-h3 as an immunological checkpoint target, which can be neutralized to enhance the anti-tumoral response of CD8T cells, offering a new avenue for PDAC treatment.
Career Highlights
Ana Hennino has been associated with leading research institutions, including the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Centre National de la Recherche Scientifique (CNRS). Her work has not only contributed to academic advancements but has also paved the way for potential clinical applications that could improve patient outcomes in the fight against pancreatic cancer.
Collaborations
Throughout her career, Hennino has collaborated with esteemed colleagues such as Kim In-San and Philippe Bertolino. These partnerships have enabled her to engage in innovative research and enhance the overall quality of her contributions to the field.
Conclusion
Ana Hennino stands out as a significant figure in the realm of cancer research and diagnostics. Her innovative methods for assessing the risk of pancreatic ductal adenocarcinoma and corresponding treatment strategies are poised to make a substantial impact in the medical community. As research progresses, her discoveries hold the potential to change the landscape of PDAC diagnosis and therapy, exemplifying the importance of innovation in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile